AR076040A1 - Composicion que comprende al menos un compuesto flavonoide, con la condicion de que el compuesto flavonoide no sea hesperetina, y hesperetina - Google Patents

Composicion que comprende al menos un compuesto flavonoide, con la condicion de que el compuesto flavonoide no sea hesperetina, y hesperetina

Info

Publication number
AR076040A1
AR076040A1 ARP100101092A ARP100101092A AR076040A1 AR 076040 A1 AR076040 A1 AR 076040A1 AR P100101092 A ARP100101092 A AR P100101092A AR P100101092 A ARP100101092 A AR P100101092A AR 076040 A1 AR076040 A1 AR 076040A1
Authority
AR
Argentina
Prior art keywords
use according
hesperetin
flavonoid compound
treating
preventing
Prior art date
Application number
ARP100101092A
Other languages
English (en)
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40908614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of AR076040A1 publication Critical patent/AR076040A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Fodder In General (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicacion 2: Uso de acuerdo con la reivindicacion 1, caracterizado porque el compuesto flavonoide se selecciona del grupo de compuestos con la siguiente formula general (1), donde los carbonos 3, 5, 6, 7, 8, 2', 3', 4', 5' y/o 6' se sustituyen en la misma forma o en una forma diferente entre si con un grupo H, OH, u OCH3, con la condicion de que el compuesto no sea hesperetina. Reivindicacion 8: Uso de acuerdo con una de las reivindicaciones precedentes, caracterizado porque es para aumentar las defensas antioxidativas de un organismo. Reivindicacion 9: Uso de acuerdo con una de las reivindicaciones precedentes, caracterizado porque es para tratar o prevenir la inflamacion. Reivindicacion 10: Uso de acuerdo con una de las reivindicaciones precedentes, caracterizado porque es para proteger un organismo contra toxinas. Reivindicacion 11: Uso de acuerdo con una de las reivindicaciones precedentes, caracterizado porque es para tratar o prevenir la formacion de venas varicosas, hemorroides, o ulceras venosas. Reivindicacion 12: Uso de acuerdo con una de las reivindicaciones precedentes, caracterizado porque es para tratar o prevenir niveles elevados de colesterol, para aumentar los niveles de colesterol HDL yio para reducir los niveles de triglicéridos en la sangre. Reivindicacion 13: Uso de acuerdo con una de las reivindicaciones precedentes, caracterizado porque es para tratar o prevenir infecciones virales, en particular herpes simple tipo l y/o infecciones por influenza. Reivindicacion 14: Uso de acuerdo con una de las reivindicaciones precedentes, caracterizado porque es para tratar, prevenir o reducir el crecimiento del cáncer. Reivindicacion 15: Una composicion caracterizada porque comprende al menos un compuesto flavonoide, con la condicion de que el compuesto flavonoide no sea hesperetina, y hesperetina, donde cada uno de al menos un compuesto flavonoide y hesperetina están presentes en una cantidad de 10 ng -10000 mg por dosis diaria.
ARP100101092A 2009-03-31 2010-03-31 Composicion que comprende al menos un compuesto flavonoide, con la condicion de que el compuesto flavonoide no sea hesperetina, y hesperetina AR076040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09156910A EP2241313A1 (en) 2009-03-31 2009-03-31 Use of flavonoids to increase the bioavailability of hesperetin

Publications (1)

Publication Number Publication Date
AR076040A1 true AR076040A1 (es) 2011-05-11

Family

ID=40908614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101092A AR076040A1 (es) 2009-03-31 2010-03-31 Composicion que comprende al menos un compuesto flavonoide, con la condicion de que el compuesto flavonoide no sea hesperetina, y hesperetina

Country Status (11)

Country Link
US (1) US8685935B2 (es)
EP (2) EP2241313A1 (es)
JP (1) JP2012522030A (es)
CN (1) CN102448455A (es)
AR (1) AR076040A1 (es)
AU (1) AU2010230211A1 (es)
BR (1) BRPI1014083A2 (es)
CL (1) CL2011002451A1 (es)
MX (1) MX2011010376A (es)
SG (1) SG174609A1 (es)
WO (1) WO2010112510A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234310A1 (en) * 2009-03-11 2010-09-16 Bionovo, Inc. Estrogenic compounds and their methods of use
CN103462957A (zh) * 2012-06-07 2013-12-25 上海中医药大学 一种异鼠李素的新用途
CN102697768A (zh) * 2012-06-07 2012-10-03 中国人民解放军第二军医大学 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途
US9053152B2 (en) 2012-08-06 2015-06-09 Sap Portals Israel Ltd Search and context based creation in dynamic workspaces
CN102861090A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid C在治疗胆管癌药物中的应用
CN102861050A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid A在治疗胰腺癌药物中的应用
CN102861053B (zh) * 2012-10-27 2013-07-10 南京大学 Houttuynoid D在治疗白血病药物中的应用
CN102861075A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid B在治疗胃癌药物中的应用
CN102861081A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid C在治疗皮肤癌药物中的应用
CN102861046A (zh) * 2012-10-27 2013-01-09 南京大学 Houttuynoid A在治疗卵巢癌药物中的应用
CN102861092A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid C在治疗肺癌药物中的应用
CN102861086A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid E在治疗卵巢癌药物中的应用
CN102861048A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid A在治疗鼻咽癌药物中的应用
CN102861060A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid B在治疗白血病药物中的应用
EP2925160B1 (en) * 2012-11-29 2018-03-14 Nestec S.A. Increasing the bioavailability of flavan-3-ols by polyphenols
GB201407694D0 (en) * 2014-05-01 2014-06-18 Univ Montfort Compound
AU2016217912A1 (en) * 2015-02-11 2017-09-28 Bioactor Bv Compounds and compositions for improving power output and oxygen efficiency
US10383842B2 (en) * 2015-02-13 2019-08-20 Global Biolife Inc. Method and composition for preventing and treating viral infections
US20210299088A1 (en) * 2015-02-13 2021-09-30 Global Biolife Inc. Method and composition for preventing and treating viral infections
JP6881890B2 (ja) * 2015-05-14 2021-06-02 花王株式会社 カテキン類吸収促進剤
US10123991B2 (en) * 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN105167193B (zh) * 2015-06-17 2019-02-19 湖北中烟工业有限责任公司 含黄酮香精的烟用嘴棒及其制备方法
CN104983728B (zh) * 2015-08-07 2018-01-05 上海中医药大学 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用
KR101725461B1 (ko) * 2015-12-29 2017-04-10 연세대학교 산학협력단 디오스민을 유효성분으로 포함하는 탈모 예방 또는 치료용, 또는 발모 또는 육모 촉진용 조성물
AU2017429594B2 (en) * 2017-08-28 2024-05-30 Global Biolife Inc. Method and composition for preventing and treating viral infections
JP2019151568A (ja) * 2018-03-01 2019-09-12 アサヒ飲料株式会社 酸性スフィンゴミエリナーゼ活性向上剤、酸性スフィンゴミエリナーゼ活性向上用組成物、及び抗アレルギー用組成物
KR20200091271A (ko) * 2019-01-22 2020-07-30 조선대학교산학협력단 헤스페레틴을 포함하는 피부과민반응을 조절하기 위한 조성물
KR20210021827A (ko) 2019-08-19 2021-03-02 연세대학교 산학협력단 켐페라이드를 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물
CN111281866B (zh) * 2020-03-30 2021-09-28 中国药科大学 一种预防或治疗溃疡性结肠炎的中药化学制剂
CN112569246A (zh) * 2020-12-22 2021-03-30 成都大学 用于抗炎镇痛止血的药物及药物活性组分筛选方法
CN114948977B (zh) * 2021-02-25 2023-11-28 南京中医药大学 二氢黄酮苷衍生物在制备防治结肠炎的药物中的用途
CN113679733A (zh) * 2021-08-31 2021-11-23 广东金骏康生物技术有限公司 一种抑制结肠炎的化合物及其应用
US11903517B2 (en) * 2021-11-16 2024-02-20 Daito Giken, Inc. Coffee machine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695181A1 (en) 1993-04-20 1996-02-07 The Procter & Gamble Company Methods of using hesperetin for sebum control and treatment of acne
JPH08283154A (ja) * 1995-04-12 1996-10-29 Nippon Shinyaku Co Ltd 脂質代謝改善剤
JP4846141B2 (ja) * 2001-08-31 2011-12-28 東洋精糖株式会社 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
JP5419366B2 (ja) * 2008-03-03 2014-02-19 東洋精糖株式会社 生体吸収性に優れたヘスペレチン組成物

Also Published As

Publication number Publication date
WO2010112510A1 (en) 2010-10-07
JP2012522030A (ja) 2012-09-20
EP2413928A1 (en) 2012-02-08
CL2011002451A1 (es) 2012-04-20
SG174609A1 (en) 2011-10-28
CN102448455A (zh) 2012-05-09
MX2011010376A (es) 2011-10-12
BRPI1014083A2 (pt) 2016-04-19
US20120022010A1 (en) 2012-01-26
US8685935B2 (en) 2014-04-01
AU2010230211A1 (en) 2011-11-03
EP2241313A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
AR076040A1 (es) Composicion que comprende al menos un compuesto flavonoide, con la condicion de que el compuesto flavonoide no sea hesperetina, y hesperetina
WO2013022846A3 (en) Flavonoid compounds
FI3743053T3 (fi) Kannabinoidien käyttö epilepsian hoidossa
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
AR022076A1 (es) Composicion antioxidante constituida por acetil l-carnitina y acido alfa-lipoico para mejorar el aprovechamiento metabolico de la glucosa
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
BR112016013481A2 (pt) composição farmacêutica, composição farmacêutica para uso, e, uso não terapêutico de uma composição
BR112012023021A2 (pt) compostos de indazol e seus usos
ECSP099376A (es) Inhibidores de la actividad de la akt
BR112014017650A8 (pt) Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson
CO6410306A2 (es) Inhibidor de sglt2 para tratar diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, alteración de la tolerancia a la glucosa e hiperglucemia
CL2011002849A1 (es) Composicion anti-inflamatoria que comprende microorganismos sometidos a tratamiento a por lo menos 71,5 grados celsius durante por lo menos 1 segundo; uso de una composicion para tratar o prevenir padecimientos inflamatorios; metodos para proporcionar los microorganismos.
EA201190219A1 (ru) Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
ECSP11010995A (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
AR075274A1 (es) Agente de tratamiento de semillas y metodo para proteger una planta
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek

Legal Events

Date Code Title Description
FB Suspension of granting procedure